Local report of cytokine landscape of SARS-CoV-2 infected patients in Chihuahua, Mexico |Biomedgrid

In December 2019, the first cases of a highly infectious disease causing severe acute respiratory syndrome were registered. In early 2020, Chinese authorities isolated and identified a new type of coronavirus, SARS-CoV-2. Currently, there are studies and controversies in the relationship of the progression of the disease with the cytokine release syndrome observed in infected patients. In this study, the levels of the cytokines IL-6, IL-8, IL-10, IL-1β, TNF-α and IL-12p70, were evaluated by Cytometric Bead Array methodology in 42 severely ill patients with Covid-19, admitted to the Hospital Central Universitario of the city of Chihuahua. Nevertheless limited, it was possible to assess the effect of ruxolitinib and dexamethasone treatments on the cytokine profile. Finally, the concentrations of the cytokines and the comorbidities that the patients presented at the time of admission were correlated. A significant increase in plasma levels of IL-6, IL-8, IL-10 and IL-1β was found in severely ill patients with Covid-19. Patients infected and treated with ruxolitinib exhibited a significant decrease in IL-6 and IL-10 levels five days after admission, thus improving their hyperinflammatory state. Cytokine levels in the Chihuahua population were found to be significantly higher in people with a high BMI and / or type 2 diabetes mellitus.